---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-327268"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:13:08.107078+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Atea reports Q3 net loss $28.2M; plans Phase 3 MORNINGSKY amendment with new primary endpoint

## Summary
- Net loss $28.2M for Q3 2021 vs $17.6M loss in Q3 2020; collaboration revenue $32.8M from Roche license.
- Cash and equivalents $839.7M as of Sept 30, 2021, down from $850.1M at Dec 31, 2020.
- Phase 3 MORNINGSKY amendment: primary endpoint to hospitalization/death; focus on unvaccinated high-risk; dose increased to 1,100 mg BID; data H2 2022.
- New infectious virus data from Phase 2 MOONSONG show rapid viral load reduction (-0.5 log10) with AT-527 1,100 mg BID vs placebo at Day 3 in overall population.
- In vitro data show AT-511 (free base of AT-527) maintains potency against variants including Delta.

## SEC filing metadata
- accession: 0001193125-21-327268
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312521327268/0001193125-21-327268-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312521327268/d249281d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-327268
- JSON: https://secwatch.observer/filing/0001193125-21-327268.json
- Plain text: https://secwatch.observer/filing/0001193125-21-327268.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.